Correction: Up-regulation of hepatoma-derived growth factor facilities tumor progression in malignant melanoma (PLoS ONE (2013) 8, 3 (e59345) DOI: 10.1371/journal.pone.0059345);Up-Regulation of Hepatoma-Derived Growth Factor Facilities Tumor Progression in Malignant Melanoma

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Tsai, Han En ^a   Wu, Jian Ching ^a   Kung, Mei Lang ^b   Liu, Li Feng ^c   Kuo, Lai Hsin ^a   Kuo, Hsiao Mei ^d   Chen, San Cher ^a   Chan, Elsa C ^f   Wu, Chieh Shan ^e   Tai, Ming Hong ^a   Liu, Guei Sheung ^f  

^a NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOMA DERIVED GROWTH FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HEPATOMA DERIVED GROWTH FACTOR GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; MELANOCYTE; MELANOMA; MELANOMA CELL; METASTATIC MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR PROMOTION; TUMOR VASCULARIZATION; UPREGULATION;

MUS;

EID: 84875413015     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/annotation/02369930-29de-4cd6-a059-9520af0be6b9     Document Type: Erratum

References (31)

1. de Vries E, Coebergh JW, (2004) Cutaneous malignant melanoma in Europe. Eur J Cancer 40: 2355-2366.
2. Rigel DS, Carucci JA (2000) Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J Clin 50: 215-236; quiz 237-240.
3. Grabacka M, Plonka PM, Urbanska K, Reiss K, (2006) Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin Cancer Res 12: 3028-3036.
4. Guo RR, Liu Y, Lu WL, Zhao JH, Wang XQ, et al. (2008) A recombinant peptide, hirudin, potentiates the inhibitory effects of stealthy liposomal vinblastine on the growth and metastasis of melanoma. Biol Pharm Bull 31: 696-702.
5. Nakamura H, Izumoto Y, Kambe H, Kuroda T, Mori T, et al. (1994) Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem 269: 25143-25149.
6. Nakamura H, Kambe H, Egawa T, Kimura Y, Ito H, et al. (1989) Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta 183: 273-284.
7. Klagsbrun M, Sasse J, Sullivan R, Smith JA, (1986) Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor. Proc Natl Acad Sci U S A 83: 2448-2452.
8. Everett AD, Stoops T, McNamara CA, (2001) Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem 276: 37564-37568.
9. Hu TH, Huang CC, Liu LF, Lin PR, Liu SY, et al. (2003) Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Cancer 98: 1444-1456.
10. Bernard K, Litman E, Fitzpatrick JL, Shellman YG, Argast G, et al. (2003) Functional proteomic analysis of melanoma progression. Cancer Res 63: 6716-6725.
11. Zhang J, Ren H, Yuan P, Lang W, Zhang L, et al. (2006) Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res 66: 18-23.
12. Chang KC, Tai MH, Lin JW, Wang CC, Huang CC, et al. (2007) Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. Int J Cancer 121: 1059-1065.
13. Uyama H, Tomita Y, Nakamura H, Nakamori S, Zhang B, et al. (2006) Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res 12: 6043-6048.
14. Yamamoto S, Tomita Y, Hoshida Y, Takiguchi S, Fujiwara Y, et al. (2006) Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res 12: 117-122.
15. Yamamoto S, Tomita Y, Hoshida Y, Morii E, Yasuda T, et al. (2007) Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol 14: 2141-2149.
16. Okuda Y, Nakamura H, Yoshida K, Enomoto H, Uyama H, et al. (2003) Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci 94: 1034-1041.
17. Everett AD, Narron JV, Stoops T, Nakamura H, Tucker A, (2004) Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol 286: L1194-1201.
18. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, et al. (1999) Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 59: 2747-2753.
19. Liu GS, Liu LF, Lin CJ, Tseng JC, Chuang MJ, et al. (2006) Gene transfer of pro-opiomelanocortin prohormone suppressed the growth and metastasis of melanoma: involvement of alpha-melanocyte-stimulating hormone-mediated inhibition of the nuclear factor kappaB/cyclooxygenase-2 pathway. Mol Pharmacol 69: 440-451.
20. Chen SC, Kung ML, Hu TH, Chen HY, Wu JC, et al. (2012) Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial-mesenchymal transition. J Pathol 228: 158-169.
21. Liu GS, Peshavariya H, Higuchi M, Brewer AC, Chang CW, et al. (2012) Microphthalmia-associated transcription factor modulates expression of NADPH oxidase type 4: a negative regulator of melanogenesis. Free Radic Biol Med 52: 1835-1843.
22. Tsai CN, Tsai CL, Tse KP, Chang HY, Chang YS, (2002) The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci U S A 99: 10084-10089.
23. Mosevitsky MI, Novitskaya VA, Iogannsen MG, Zabezhinsky MA, (1989) Tissue specificity of nucleo-cytoplasmic distribution of HMG1 and HMG2 proteins and their probable functions. Eur J Biochem 185: 303-310.
24. Folkman J, Merler E, Abernathy C, Williams G, (1971) Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133: 275-288.
25. Mahabeleshwar GH, Byzova TV, (2007) Angiogenesis in melanoma. Semin Oncol 34: 555-565.
26. Lee KH, Choi EY, Kim MK, Lee SH, Jang BI, et al. (2010) Hepatoma-derived growth factor regulates the bad-mediated apoptotic pathway and induction of vascular endothelial growth factor in stomach cancer cells. Oncol Res 19: 67-76.
27. Gavert N, Ben-Ze'ev A, (2008) Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med 14: 199-209.
28. Bonitsis N, Batistatou A, Karantima S, Charalabopoulos K, (2006) The role of cadherin/catenin complex in malignant melanoma. Exp Oncol 28: 187-193.
29. Mikesh LM, Kumar M, Erdag G, Hogan KT, Molhoek KR, et al. (2010) Evaluation of molecular markers of mesenchymal phenotype in melanoma. Melanoma Res 20: 485-495.
30. Kao YH, Chen CL, Jawan B, Chung YH, Sun CK, et al. (2010) Upregulation of hepatoma-derived growth factor is involved in murine hepatic fibrogenesis. J Hepatol 52: 96-105.
31. Kung ML, Tsai HE, Hu TH, Kuo HM, Liu LF, et al. (2012) Hepatoma-derived growth factor stimulates podosome rosettes formation in NIH/3T3 cells through the activation of phosphatidylinositol 3-kinase/Akt pathway. Biochem Biophys Res Commun 425: 169-176.